LUND, Sweden, Sept. 13, 2021 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a diagnostic company that develops and sells
highly accurate blood tests for the early detection of cancer,
today announced that Immunovia has strengthened its patent
protection for pancreatic cancer biomarkers by obtaining a global
license from the South Korean company JW BioScience's IP
The license agreement gives Immunovia global commercial rights
for two biomarkers for early detection of pancreatic cancer. The
biomarkers are also part of Immunovia, Inc.'s IMMray™ PanCan-d
biomarker signature. Immunovia discovered these pancreatic cancer
biomarkers independently of JW BioScience and have now fully
secured intellectual property rights.
The details and deal size of this contract are not disclosed as
agreed by both parties.
Patrik Dahlen, CEO of Immunovia,
said, "We are delighted to enter into this agreement that further
secures relevant IP and validates our biomarker discovery approach.
By entering into this agreement, Immunovia and JW BioScience will
also evaluate possibilities for commercial collaboration to enable
early detection of pancreatic cancer in the Korean market."
Eun-Kyung Hahm, CEO of JW
Bioscience, said, "This contract is an important milestone for JW's
unique IP position and a recognition of the excellence of JW
technology in the global market." She also added that, "JW will be
able to further strengthen its commercial and technological
competitiveness through the collaboration with Immunovia."
Immunovia has a strong and extensive IP portfolio consisting of
seven patent families, covering biomarkers in pancreatic
About JW Bioscience
JW Bioscience is a company that focuses on R&D of diagnostic
reagents and medical devices. The commercialization of high
value-added in-vitro diagnostic kits is ongoing based on the
original technology in diagnostic fields such as sepsis and
pancreatic cancer. In addition, they are developing a
`Point-of-Care Testing (POCT)' product that enables simple and
quick diagnosis. The company is also a forerunner in the
localization of essential medical devices through products
developed with its own technology, such as LED astral lamp and
In December 2020, it was
incorporated as a subsidiary of JW Life Science within the JW
group, a company specialized in the production of infusions. With
the stable financial power, JW Life Sciences plans to secure the
future growth engines by increasing the R&D investment in
diagnostic reagents as well as the high value-added nutritional
JW Life Sciences is listed on the KOSPI as `034080'.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1, and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB